Preventive health technologies-;such as wrist-worn activity trackers or health and fitness apps-;are popular tools for promoting wellbeing, but new research published in the Journal of Consumer Affairs reveals that consumer engagement with these technologies can be considered a double-edged sword.
Ifinatamab deruxtecan by Daiichi Sankyo for Lymphoma: Likelihood of Approval
Ifinatamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Lymphoma.